Effectiveness of respiratory syncytial virus immunisation in practice.

Authors

Rosalie W Groenendijk, Zazie Franck, Ranju Baral, Leonardo J Basso, Facundo D Batista, Marc Bonten, Mauricio T Caballero, Andrew Clark, Cheryl Cohen, Matthieu Domenech de Cellès, Ignacio Esteban, Ann R Falsey, Slim Fourati, Barney S Graham, Natasha Halasa, Tina Hartert, Aranka L Kops, Leyla Kragten-Tabatabaie, Lies Kriek, Paolo Manzoni, David J Marchant, Federico Martinon-Torres, Asuncion Mejias, Fabio Midulla, Annettee Nakimuli, M Imran Nisar, Joyce U Nyiro, Pedro A Piedra, Peter C Richmond, Farina L Shaaban, Padmini Srikantiah, Renato T Stein, Afshan B Tahibo, Jonne Terstappen, Mariana Viegas, Carla Vizzotti, Conall H Watson, Liang En Wee, Daniel M Weinberger, Louis J Bont, Natalie I Mazur

Published in

The Lancet. Infectious diseases. Oct 20, 2026. Epub Oct 20, 2026.

Abstract

Respiratory syncytial virus (RSV) affects all ages, with infants and older adults most affected by severe disease. The RSV prevention landscape includes 39 candidates in clinical development, alongside setbacks such as the discontinuation of a promising paediatric live-attenuated vaccine candidate. Several products have been approved, including a maternal vaccine, infant monoclonal antibodies, and vaccines for older adults and adults at high risk. Due to high cost, implementation of these products remains limited to higher-income settings. Real-world evidence confirms high effectiveness, with emerging benefits beyond respiratory disease, including reduced cardiovascular events in older adults. Despite comparable effectiveness of maternal vaccination and monoclonal antibodies, differences in uptake highlight that product availability alone will not ensure population impact. Achieving uptake requires integration into accessible routine care, recommendation by trusted providers, and context-sensitive delivery strategies. This Review summarises RSV preventive products, real-world effectiveness and uptake, and the opportunity of using communication in translating RSV prevention into impact.

PMID:
42901195
Bibliographic data and abstract were imported from PubMed on 21 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.